Inhibitors of cyclo-oxygenase-2 and secretory phospholipase A2 preserve bone architecture following ovariectomy in adult rats

Bone

Volumn 39, Issue 1, 2006, Pages 134-142

  Gregory, Laura S ^a   Kelly, Wendy L ^a   Reid, Robert C ^a   Fairlie, David P ^a   Forwood, Mark R ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Arachidonic acid; Bone remodeling; Cyclooxygenase isoforms; Osteoclasts; Phospholipase A2

Indexed keywords

CYCLOOXYGENASE 2; PHOSPHOLIPASE A2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE REMODELING; CELL ACTIVATION; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; MORPHOMETRICS; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OVARIECTOMY; RAT; TRABECULAR BONE;

ANIMALS; BONE AND BONES; BONE RESORPTION; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGENS; FEMALE; FURANS; OVARIECTOMY; PENTANOIC ACIDS; PHOSPHOLIPASES A; RATS; RATS, WISTAR;

EID: 33646877375     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2005.12.017     Document Type: Article

References (59)

1. Forwood M.R. Inducible cyclo-oxygenase (COX-2) mediates the induction of bone formation by mechanical loading in vivo. J. Bone Miner. Res. 11 (1996) 1688-1693
2. Li J., Burr D.B., and Turner C.H. Suppression of prostaglandin synthesis with NS-398 has different effects on endocortical and periosteal bone formation induced by mechanical loading. Calcif. Tissue Int. 70 (2002) 320-329
3. Okada Y., Lorenzo J.A., Freeman A.M., Tomita M., Morham S.G., Raisz L.G., et al. Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast-like cells in culture. J. Clin. Invest. 105 (2000) 823-832
4. Smith W.L., Garavito R.M., and DeWitt D.L. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J. Biol. Chem. 271 (1996) 33157-33160
5. Garcia C., Qiao M., Chen D., Kirchen M., Gallwitz W., Mundy G.R., et al. Effects of synthetic peptido-leukotrienes on bone resorption in vitro. J. Bone Miner. Res. 11 (1996) 521-529
6. Hirabayashi T., Murayama T., and Shimizu T. Regulatory mechanism and physiological role of cytosolic phospholipase A2. Biol. Pharm. Bull. 27 (2004) 1168-1173
7. Kawaguchi H., Nemoto K., Raisz L.G., Harrison J.R., Voznesensky O.S., Alander C.B., et al. Interleukin-4 inhibits prostaglandin G/H synthase-2 and cytosolic phospholipase A2 induction in neonatal mouse parietal bone cultures. J. Bone Miner. Res. 11 (1996) 358-366
8. Kawaguchi H., Pilbeam C.C., Vargas S.J., Morse E.E., Lorenzo J.A., and Raisz L.G. Ovariectomy enhances and estrogen replacement inhibits the activity of bone marrow factors that stimulate prostaglandin production in cultured mouse calvariae. J. Clin. Invest. 96 (1995) 539-548
9. Rawlinson S.C.F., Wheeler-Jones C.P.D., and Lanyon L.E. Arachidonic acid for loading induced prostacyclin and prostaglandin E2 release from osteoblasts and osteocytes is derived from the activities of different forms of phospholipase A2. Bone 27 (2000) 241-247
10. Ellies L.G., Heersche J.N., Vadas P., Pruzanski W., Stefanski E., and Aubin J.E. Interleukin-1 alpha stimulates the release of prostaglandin E2 and phospholipase A2 from fetal rat calvarial cells in vitro: relationship to bone nodule formation. J. Bone Miner. Res. 6 (1991) 843-850
11. Ajubi N.E., Klein-Nulend J., Alblas M.J., Burger E.H., and Nijweide P.J. Signal transduction pathways involved in fluid flow-induced PGE2 production by cultured osteocytes. Am. J. Physiol. 276 (1999) E171-E178
12. Fonteh A.N., Atsumi G., LaPorte T., and Chilton F.H. Secretory phospholipase A2 receptor-mediated activation of cytosolic phospholipase A2 in murine bone marrow-derived mast cells. J. Immunol. 165 (2000) 2773-2782
13. Fonteh A.N., Samet J.M., Surette M., Reed W., and Chilton F.H. Mechanisms that account for the selective release of arachidonic acid from intact cells by secretory phospholipase A2. Biochim. Biophys. Acta 1393 (1998) 253-266
14. Bonventre J. Cytosolic phospholipase A2alpha reigns supreme in arthritis and bone resorption. Trends Immunol. 25 (2004) 116-119
15. Miyaura C., Inada M., Matsumoto C., Ohshiba T., Uozumi N., Shimizu T., and Ito A. An essential role of cytosolic phospholipase A2alpha in prostaglandin E2-mediated bone resorption associated with inflammation. J. Exp. Med. 197 (2003) 1303-1310
16. Pilbeam C.C., Raisz L.G., Voznesensky O., Alander C.B., Delman B.N., and Kawaguchi H. Autoregulation of inducible prostaglandin G/H synthase in osteoblastic cells by prostaglandins. J. Bone Miner. Res. 10 (1995) 406-414
17. Chen Q.R., Miyaura C., Higashi S., Murakami M., Kudo I., Saito S., et al. Activation of cytosolic phospholipase A2 by platelet-derived growth factor is essential for cyclooxygenase-2-dependent prostaglandin E2 synthesis in mouse osteoblasts cultured with interleukin-1. J. Biol. Chem. 272 (1997) 5952-5958
18. Kolko M., Rodriguez de Turco E.B., Diemer N.H., and Bazan N.G. Neuronal damage by secretory phospholipase A2: modulation by cytosolic phospholipase A2, platelet-activating factor, and cyclooxygenase-2 in neuronal cells in culture. Neurosci. Lett. 338 (2003) 164-168
19. Seibert K., and Masferrer J.L. Role of inducible cyclooxygenase (COX-2) in inflammation. Receptor 4 (1994) 17-23
20. Chan C.C., Boyce S., Brideau C., Ford-Hutchinson A.W., Gordon R., Guay D., et al. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J. Pharmacol. Exp. Ther. 274 (1995) 1531-1537
21. Altman R.D., Latta L.L., Keer R., Renfree K., Hornicek F.J., and Banovac K. Effect of nonsteroidal antiinflammatory drugs on fracture healing: a laboratory study in rats. J. Orthop. Trauma 9 (1995) 392-400
22. Simon A., Manigrasso M., and O'Connor J. Cyclo-oxygenase 2 function is essential for bone fracture healing. J. Bone Miner. Res. 17 (2002) 963-976
23. Zhang X., Schwarz E.M., Young D.A., Puzas J.E., Rosier R.N., and O'Keefe R.J. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J. Clin. Invest. 109 (2002) 1405-1415
24. Sato T., Morita I., Sakaguchi K., Nakahama K.I., Smith W.L., Dewitt D.L., et al. Involvement of prostaglandin endoperoxide H synthase-2 in osteoclast-like cell formation induced by interleukin-1 beta. J. Bone Miner. Res. 11 (1996) 392-400
25. Tai H., Miyaura C., Pilbeam C.C., Tamura T., Ohsugi Y., Koishihara Y., et al. Transcriptional induction of cyclooxygenase-2 in osteoblasts is involved in interleukin-6-induced osteoclast formation. Endocrinology 138 (1997) 2372-2379
26. Morton D.J., Barrett-Connor E.L., and Schneider D.L. Nonsteroidal anti-inflammatory drugs and bone mineral density in older women: the Rancho Bernardo study. J. Bone Miner. Res. 13 (1998) 1924-1931
27. Lane N., Coble T., and Kimmel D.B. Effect of naproxen on cancellous bone in ovariectomized rats. J. Bone Miner. Res. 5 (1990) 1029-1035
28. Riendeau D., Charleson S., Cromlish W., Mancini J.A., Wong E., and Guay J. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays. Can. J. Physiol. Pharmacol. 75 (1997) 1088-1095
29. Hansford K.A., Reid R.C., Clark C.I., Tyndall J.D., Whitehouse M.W., Guthrie T., et al. d-Tyrosine as a chiral precursor to potent inhibitors of human nonpancreatic secretory phospholipase A2 (IIa) with antiinflammatory activity. ChemBioChem 4 (2003) 181-185
30. Arumugam T.V., Arnold N., Proctor L.M., Newman M., Reid R.C., Hansford K.A., et al. Comparative protection against rat intestinal reperfusion injury by a new inhibitor of sPLA2, COX-1 and COX-2 selective inhibitors, and an LTC4 receptor antagonist. Br. J. Pharmacol. 140 (2003) 71-80
31. R.C. Reid, C.I. Clark, K. Hansford, M.J. Stoermer, R.P. McGeary, K. Schafer, D.P. Fairlie, New amino acid derivatives useful for the treatment of inflammatory disease or condition. WO Patent 200208189, 2001; filed Jul 24, 2001: issued Jan 31, 2002.
32. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 2 (1987) 595-610
33. Li X.J., Jee W.S., Chow S.Y., and Woodbury D.M. Adaptation of cancellous bone to aging and immobilization in the rat: a single photon absorptiometry and histomorphometry study. Anat. Rec. 227 (1990) 12-24
34. Parfitt A.M. The physiologic and clinical significance of bone histomorphometric data. Recker RR Recker RRs. Bone Histomorphometry: Techniques and Interpretation (1983), CRC Press, Boca Raton, Florida U.S.A. 143-224
35. Oddie G.W., Schenk G., Angel N.Z., Walsh N., Guddat L.W., de Jersey J., et al. Structure, function, and regulation of tartrate-resistant acid phosphatase. Bone 27 (2000) 575-584
36. Baldock P.A., Need A.G., Moore R.J., Durbridge T.C., and Morris H.A. Discordance between bone turnover and bone loss: effects of aging and ovariectomy in the rat. J. Bone Miner. Res. 14 (1999) 1442-1448
37. Riggs B.L., and Parfitt A.M. Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J. Bone Miner. Res. 20 (2005) 177-184
38. Westerlind K.C., Wronski T.J., Ritman E.L., Luo Z.P., An K.N., Bell N.H., et al. Estrogen regulates the rate of bone turnover but bone balance in ovariectomized rats is modulated by prevailing mechanical strain. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 4199-4204
39. Nicoll-Griffith D.A., Falgueyret J.P., Silva J.M., Morin P.E., Trimble L., Chan C.C., et al. Oxidative bioactivation of the lactol prodrug of a lactone cyclooxygenase-2 inhibitor. Drug Metab. Dispos. 27 (1999) 403-409
40. Woodruff T.M., Arumugam T.V., Shiels I.A., Newman M.L., Ross P.A., Reid R.C., et al. A potent and selective inhibitor of group IIa secretory phospholipase A2 protects rats from TNBS-induced colitis. Int. Immunopharmacol. 5 (2005) 883-892
41. Bidgood M.J., Jamal O.S., Cunningham A.M., Brooks P.M., and Scott K.F. Type IIA secretory phospholipase A2 up-regulates cyclooxygenase-2 and amplifies cytokine-mediated prostaglandin production in human rheumatoid synoviocytes. J. Immunol. 165 (2000) 2790-2797
42. Triggiani M., Granata F., Balestrieri B., Petraroli A., Scalia G., Del Vecchio L., et al. Secretory phospholipases A2 activate selective functions in human eosinophils. J. Immunol. 170 (2003) 3279-3288
43. Peng Z.Q., Vaananen H.K., Zhang H.X., and Tuukkanen J. Long-term effects of ovariectomy on the mechanical properties and chemical composition of rat bone. Bone 20 (1997) 207-212
44. Baron R., Tross R., and Vignery A. Evidence of sequential remodeling in rat trabecular bone: morphology, dynamic histomorphometry, and changes during skeletal maturation. Anat. Rec. 208 (1984) 137-145
45. Wronski T.J., Cintron M., and Dann L.M. Temporal relationship between bone loss and increased bone turnover in ovariectomized rats. Calcif. Tissue Int. 43 (1988) 179-183
46. Li J., Mori S., Mashiba T., Kaji Y., Taki M., Komatsubara S., et al. Preadministration of incadronate disodium can prevent bone loss in rat proximal tibial metaphysis when induced by hindlimb immobilization by bandage. Bone 23 (1998) 459-463
47. Kimmel D.B., Coble T., and Lane N. Long-term effect of naproxen on cancellous bone in ovariectomized rats. Bone 13 (1992) 167-172
48. Parfitt A.M. Trabecular bone architecture in the pathogenesis and prevention of fracture. Am. J. Med. 82 (1987) 68-72
49. Pugh J.W., Rose R.M., and Radin E.L. A structural model for the mechanical behavior of trabecular bone. J. Biomech. 6 (1973) 657-670
50. Pugh J.W., Rose R.M., and Radin E.L. Elastic and viscoelastic properties of trabecular bone: dependence on structure. J. Biomech. 6 (1973) 475-485
51. Parkinson I.H., and Fazzalari N.L. Interrelationships between structural parameters of cancellous bone reveal accelerated structural change at low bone volume. J. Bone Miner. Res. 18 (2003) 2200-2205
52. Kleerekoper M., Villanueva A.R., Stanciu J., Rao D.S., and Parfitt A.M. The role of three-dimensional trabecular microstructure in the pathogenesis of vertebral compression fractures. Calcif. Tissue Int. 37 (1985) 594-597
53. Kudo I., and Murakami M. Phospholipase A2 enzymes. Prostaglandins Other Lipid Mediat. 68-69 (2002) 3-58
54. Rapuano B.E., and Bockman R.S. Protein kinase C-independent activation of a novel nonspecific phospholipase C pathway by phorbol myristate acetate releases arachidonic acid for prostaglandin synthesis in MC3T3-E1 osteoblasts. Prostaglandins 53 (1997) 163-186
55. Kozawa O., Suzuki A., Shinoda J., Ozaki N., Oiso Y., and Uematsu T. Involvement of phospholipase D activation in endothelin-1-induced release of arachidonic acid in osteoblast-like cells. J. Cell. Biochem. 64 (1997) 376-381
56. Watanabe-Tomita Y., Suzuki A., Shinoda J., Oiso Y., and Kozawa O. Arachidonic acid release induced by extracellular ATP in osteoblasts: role of phospholipase D. Prostaglandins Leukot. Essent. Fat. Acids 57 (1997) 335-339
57. Higashi S., Ohishi H., and Kudo I. Augmented prostaglandin E2 generation resulting from increased activities of cytosolic and secretory phospholipase A2 and induction of cyclooxygenase-2 in interleukin-1 beta-stimulated rat calvarial cells during the mineralizing phase. Inflamm. Res. 49 (2000) 102-111
58. Garcia C., Boyce B.F., Gilles J., Dallas M., Qiao M., Mundy G.R., et al. Leukotriene B4 stimulates osteoclastic bone resorption both in vitro and in vivo. J. Bone Miner. Res. 11 (1996) 1619-1627
59. Hikiji H., Ishii S., Shindou H., Takato T., and Shimizu T. Absence of platelet-activating factor receptor protects mice from osteoporosis following ovariectomy. J. Clin. Invest. 114 (2004) 85-93